2 results
Approved WMORecruiting
To assess the feasibility and efficacy of 90Y-ibritumomab tiuxetan consolidation treatment after R-PECC chemotherapy as second or third line treatment in patients with refractory or relapsed aggressive B-cell NHL, after or not eligible for…
Approved WMORecruiting
The primary objective is to compare the pharmacological profile of the magistral form of dexamphetamine sulphate to the pharmacological profile of the brand-name form of dexamphetamine (Tentin©) in adult patients diagnosed with attention deficit…